La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Petros Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Petros Pharma..

Petros Pharma (NASDAQ:PTPI) Azioni, Catena delle Opzioni

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

Shares of Block Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) tumbled in early trading on Friday, after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41826457/block-shares-sink-after-mixed-q3-results-eps-beat-revenues-miss">mixed third-quarter results</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<ul>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/60216a57879cba00010f246b/david-williams">analyst Mayank Tandon</a> maintained a Buy rating, while raising the price target from $80 to $90.</li>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58f777c10bd99100018a435e/tien-tsin-huang">analyst Tien-tsin Huang</a> reiterated an Overweight rating and price target of $90.</li>
<li>Stephens <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/624d5d9d72b50e0001afdf24/charles-nabhan">analyst Charles Nabhan</a> reaffirmed an Overweight rating and price target of $90.</li>
<li>Oppenheimer <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d3cdb8b85e930001808a5c/rayna-kumar">analyst Rayna Kumar</a> maintained a Perform rating on the stock.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Needham: Block's GPV (gross payment volume) came in at $62.5 billion, up 4% year-on-year, but missed consensus of $64.33 billion consensus, while gross profit of $2.25 billion, beat consensus of $2.24 billion, Tandon said. Although GPV weakness weighed on transaction revenues, "healthy margins and operating leverage fueled better profitability," he added.
The company raised its full-year guidance due to better third-quarter results, but its fourth-quarter outlook was "lighter than expected on both gross profit and EBITDA," the analyst stated. "We believe the softer 4Q guide reflects persistent pressure on Seller GPV growth and higher than expected investments in sales and marketing," he further wrote.
JPMorgan: Block's quarterly results were "solid," but the negative surprise was a reduction in the fourth-quarter guidance, Huang said. Management's preliminary 2025 outlook of at least 15% growth in gross profit "assumes acceleration through the year inclusive of improving Square GPV growth, a critical watch item for investors given underperformance vs. peers and the market," he added.
"With this guide, the execution bar has been set higher for next year," the analyst wrote. While gross profit growth decelerated through the year in 2024, Block will need to "accelerate from a +14% exit rate in FY24, putting its various product, GTM and organizational initiatives to the test for it to achieve similar upside as it has this year," he further wrote.
Stephens: Block's third-quarter beat was driven by expense control, Nabhan said. Cash App's gross profit grew by 21% year-on-year, while Square's gross profit rose 16%, with GPV decelerating to 7.6% year-on-year, from 8% in the second quarter, he added.
The company raised its full-year adjusted operating income by $120 million, which reflected the third-quarter beat, the analyst stated. "Given GP growth/adj op margin of 18%, the outlook equates to 36% on a rule of 40 basis, vs. 35% prior," he further wrote.
Oppenheimer: Block's adjusted EBITDA grew 69% to $807 million and beat consensus of $707 million, but total GPV rose by only 2%, missing Street&#8217;s 5% estimate, Kumar said. Cash App's GPV contracted by 40%, versus Street&#8217;s estimate of a 9% decline, while Square's GPV growth of 8% came in-line with expectations, he added.
Investor concerns around the company's slowing top-line growth "were evident in results," the analyst stated. Block seems well-positioned for continued market share gains, but upside potential is limited by its "relatively high exposure to discretionary consumer spend, small businesses and the non-affluent demographic," he further wrote.
Price Action: Shares of Block had declined by 5.52% to $71.08 at the time of publication on Friday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41833692/jack-dorsey-reaffirms-blocks-bitcoin-centric-vision-to-boost-digital-wallet-mining-businesses-companys-btc-stash-grows-by-15m-in-q3">Jack Dorsey Reaffirms Block&#8217;s Bitcoin-Centric Vision To Boost Digital Wallet, Mining Businesses— Company&#8217;s BTC Stash Grows By $15M In Q3</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

Block Reports Mixed Q3, Analysts Consider Preliminary 2025 Outlook As Aggressive

Barclays analyst Saket Kalia maintains Alarm.com Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRM#NASDAQ">ALRM</a>) with a Equal-Weight and raises the price target from $60 to $67.

News

ALRM

Barclays Maintains Equal-Weight on Alarm.com Holdings, Raises Price Target to $67

BofA Securities analyst Salvator Tiano upgraded International Flavors &amp; Fragrances, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) to Buy from Neutral, <a href="https://www.benzinga.com/quote/IFF/analyst-ratings">lowering the price forecast to $107 from $109</a>.
Per the analyst, International Flavors has exceeded earnings expectations in all three quarters this year under its new CEO, while working to revitalize its R&amp;D organization and product pipeline.
The company reported third quarter net sales of $2.93 billion, up 4% year-over-year, driven by strong performance in Health &amp; Biosciences, <a href="https://www.benzinga.com/pressreleases/24/11/b41758164/iff-reports-third-quarter-2024-results">Scent, Nourish, and Pharma Solutions</a>. Volume grew high-single digits and improved across all businesses.
The analyst projects end-market demand to improve in 2025-26, following a period of pressure. Innovation is also regaining momentum after years of SKU reductions, although the analyst cautions not to overstate its impact given the current soft consumer environment.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41818982/will-microstrategys-42-billion-bitcoin-bet-boost-mstr-stock-further" target="_blank" rel="noreferrer noopener">Will MicroStrategy's $42 Billion Bitcoin Bet Boost MSTR Stock Further?</a>
Improved results are projected ahead to enable earlier deleveraging, with International Flavors having more attractive opportunities for cash use beyond just paying down debt, Tiano writes. Additionally, the company&#8217;s valuation is seen as attractive compared to historical levels and European peers.
Although the company maintained its full-year outlook, Tiano highlights an additional $30 million in incentive compensation due to better-than-expected performance, which increases next year's tailwind to $130 million.
This, along with other factors, has led the analyst to raise the 2025 EBITDA estimate to $2.265 billion, up from $2.161 billion previously. The 2026 EBITDA estimate is now projected at $2.277 billion, the analyst highlights.
Tiano raised the FY25 EPS estimate to $4.85 from $4.60, and FY26 estimate to $5.05 from $4.85.
Price Action: IFF shares are trading higher by 1.99% to $91.95&nbsp;at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41821244/blockfis-lending-license-revoked-by-california-regulator-over-violations" target="_blank" rel="noreferrer noopener">BlockFi's Lending License Revoked By California Regulator Over Violations</a></li>
</ul>

Equities

Upgrades

Markets

General

Fragrance Maker IFF Positioned For Growth With Revitalized R&D And Attractive Valuation: Analyst

Raymond James analyst Andy Marok maintains Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Outperform and raises the price target from $16 to $19.

GRND

Raymond James Maintains Outperform on Grindr, Raises Price Target to $19

Cannabis-focused consumer packaged goods company Auxly Cannabis Group Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/XLY#TSX">XLY</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTCQB">CBWTF</a>) released its financial results on Friday for the three and nine months ended Sept. 30, 2024.
&#8220;Our continued focus on efficient revenue growth and enhanced profitability has delivered another record-breaking quarter of financial results, highlighted by an 18% year-over-year increase in net revenue and record adjusted EBITDA of $8.3 million," said Hugo Alves, the company's CEO.
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Net revenue totaled CA$33.3 million ($24 million), compared to CA$28.2 million in the prior year's period, representing an increase of 18%.</li>
<li>Gross profit was CA$17.1 million, up from CA$4.6 million in the prior year's quarter.</li>
<li>Total expenses amounted to CA$14.1 million, down from CA$19.1 million in the same period of last fiscal year.</li>
<li>Net income amounted to CA$3.2 million, down from CA$31.6 million net income in the corresponding quarter of last year.</li>
<li>Adjusted EBITDA came in positive at CA$8.3 million, up from an adjusted EBITDA gain of CA$117 000 in the same quarter of last year.</li>
<li>Selling, general and administrative expenses were CA$8.5 million in the third quarter of 2024, CA$1.6 million or 16% lower than the same period in 2023.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40397950/auxly-cannabis-co-sets-q2-record-in-revenue-following-33-yoy-increase-reports-best-quarter-in-hi">Auxly Cannabis Co Sets Q2 Record In Revenue Following 33% YoY Increase, Reports Best Quarter In History</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Nine Months Ended Sept. 30, Financial Highlights</h3>
<ul>
<li>Net revenue totaled CA$87.7 million, compared to CA$74.2 million in the prior year's period, representing an increase of 18%.</li>
<li>Gross profit was CA$42.5 million, up from CA$18.5 million in the prior year's quarter.</li>
<li>Total expenses amounted to CA$46.6 million, down from CA$54.5 million in the same period of last fiscal year.</li>
<li>Net loss amounted to CA$20.8 million, compared to CA$9.5 million net income in the corresponding quarter of last year.</li>
<li>Adjusted EBITDA came in positive at CA$15.7 million, up from an adjusted EBITDA loss of $CA823 000 in the same quarter of last year.</li>
</ul>
<h3 class="wp-block-heading">Outlook</h3>
Going forward, Auxly will prioritize focused and efficient growth in its key product categories of vape, pre-roll and dried flower and continue to optimize and improve distribution and sales of its products.
<h3 class="wp-block-heading">CBWTF Price Action</h3>
Auxly's shares traded 4.57% higher at $0.0366 per share at the time of writing on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37924655/canadian-cannabis-companies-could-see-valuations-soar-by-up-to-300-with-tax-reform-">Canadian Cannabis Companies Could See Valuations Soar By Up To 300% With Tax Reform, New Report Shows</a></li>
</ul>

Cannabis

Earnings

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

TSX:XLY

Select Sector SPDR-Consumer Discretionary

Auxly Cannabis Co.: Q3 Net Revenue Climbs 18% YoY, Adjusted EBITDA Soars

Raymond James analyst Patrick Tyler Brown maintains GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) with a Outperform and raises the price target from $47 to $50.

Raymond James Maintains Outperform on GFL Environmental, Raises Price Target to $50

Raymond James analyst Adam Tindle maintains Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) with a Outperform and raises the price target from $85 to $95.

FTNT

Raymond James Maintains Outperform on Fortinet, Raises Price Target to $95

Raymond James analyst John Davis maintains Flywire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) with a Strong Buy and raises the price target from $23 to $27.

FLYW

Raymond James Maintains Strong Buy on Flywire, Raises Price Target to $27

Dave Ramsey, the well-known personal finance guru, recently shared a timeless piece of advice from his grandmother that got people talking. He posted <a href="https://x.com/DaveRamsey/status/1847373355059761518">on X</a> and other social media, &#8220;There&#8217;s a great place to go when you&#8217;re broke: to work!&#8221; It was simple, blunt and to the point, just like Ramsey&#8217;s old-school philosophy on tackling financial troubles.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">My Grandmother used to say, &quot;There&#39;s a great place to go when you&#39;re broke: to work!&quot;
&mdash; Dave Ramsey (@DaveRamsey) <a href="https://twitter.com/DaveRamsey/status/1847373355059761518?ref_src=twsrc%5Etfw">October 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year –<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing –<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
<a href="https://www.benzinga.com/personal-finance/financial-advisors/24/01/36597689/millennials-are-the-most-likely-of-all-generations-to-experience-financial-ha">Financial hardships</a> seem all too common these days, so Ramsey&#8217;s message is a reminder that getting back on your feet often starts with good old-fashioned hard work. His grandmother&#8217;s advice isn't about waiting for the right time or finding a dream job, right? Wrong. It&#8217;s about getting your hands dirty, finding any job and using that money to get out of the hole. Action, not perfection, is the key.
This philosophy has struck a nerve with many of his followers and non-followers. Some fully agree, believing hard work is the first step toward financial independence. After all, the idea that nothing beats a steady paycheck is a <a href="https://www.benzinga.com/personal-finance/24/08/40512938/dave-ramseys-blunt-advice-your-finances-are-80-behavior-avoid-this-one-costly-mistake">core part of Ramsey&#8217;s teachings</a>. He's spent years encouraging people to get rid of debt, save and ultimately invest for the future and all of that starts with earning an income.
Trending: ‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a>
However, not everyone sees it the same way. The tweet has sparked debate about what it takes to find work in today&#8217;s economy. Many have pointed out that times have changed – finding a job isn't always as easy as just showing up. One user commented, &#8220;I have been unemployed from full-time work for almost two years; I currently work three part-time jobs. If only &#x2A;wanting&#x2A; to work and earn a livable wage was all it took.&#8221; Another added, &#8220;Show me a place that's not riddled with ghost jobs and scammers and I'll apply!&#8221; referring to the many job postings that seem more like dead ends than opportunities.
See Also: This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a>
Despite the mixed reactions, the core of Ramsey&#8217;s message remains relatable for many, if not most people – when money is tight, any work is better than no work at all. And for many, that's the first step toward bigger opportunities.
After all, Ramsey recently <a href="https://www.benzinga.com/personal-finance/24/10/41146426/can-you-guess-the-top-5-careers-of-millionaires-according-to-dave-ramsey-spoiler-alert-theyre-no">brought attention to a study</a> that revealed the top five professions with the highest chance of producing billionaires and the findings may surprise you. The top careers are engineers ($91,010), accountants (CPA) ($77,250), teachers ($61,030), management ($107,360) and attorneys ($135,740).&nbsp;
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs – this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a></li>
</ul>

Startups

"There's A Great Place To Go When You're Broke: To Work," Says Dave Ramsey About A Piece Of Advice He Got

A nearly 3% Medicare payment cut for physicians is set to take effect in 2025, raising concerns about the potential impact on patient care, particularly in rural and underserved areas. The Centers for Medicare &amp; Medicaid Services (CMS) finalized the pay cut in early November, meaning physicians who provide <a href="https://www.benzinga.com/personal-finance/24/10/41570507/medicare-advantage-shake-up-how-health-insurance-plans-could-change-for-up-to-44-000-new-hampshi">Medicare-covered services</a> will see reduced reimbursement rates.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a></li>
<li>According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually,<a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor"> here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a></li>
</ul>
<h2 class="wp-block-heading">Medicare Payment Cuts</h2>
Under current rules, Medicare payments for physicians do not adjust with <a href="https://www.benzinga.com/personal-finance/24/11/41728751/even-as-inflation-cools-most-americans-cant-get-ahead-and-continue-living-paycheck-to-paycheck-r">inflation</a> as they do for hospitals, nursing homes and other health care facilities. This results in a fixed payment structure for physician services that is slowly eroded by rising operational costs.&nbsp;
As a result, many doctors feel financially squeezed, especially as their operating costs are expected to increase by an estimated 3.5% in 2025, according to CMS. The American Medical Association (AMA) has emphasized that these cuts significantly strain practices, particularly smaller ones or those in rural areas.
For the past five years, Congress has delayed or partially offset Medicare pay cuts through temporary measures, often in the final days of the legislative calendar. In 2024, lawmakers are once again discussing options to avert the cut. One bipartisan proposal, the Bipartisan Medicare Patient Access and Practice Stabilization Act, aims to stop the planned reduction and provide physicians a partial 1.8% inflationary boost.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
<h2 class="wp-block-heading">The Implications for Medicare Patients</h2>
Physician advocates worry that reducing Medicare reimbursements could limit <a href="https://www.benzinga.com/general/biotech/24/08/40422798/doctors-struggle-to-secure-medicare-coverage-for-heart-patients-on-novo-nordisks-wegovy">patients' access to care</a>.&nbsp;
"For physician practices operating on small margins already, this means it is harder to acquire new equipment, harder to retain staff, harder to take on new Medicare patients and harder to keep the doors open, particularly in rural and underserved areas," says Dr. Bruce A. Scott, President of the American Medical Association.
Dr. Scott also stated that Medicare's plan to pay physicians less while doctors' costs continue to increase is an unsustainable trend.&nbsp;
A primary concern is that providers in rural or underserved areas may feel compelled to close practices, retire earlier or reduce the number of Medicare patients they accept. Operating with lower Medicare reimbursement rates often means tighter margins for these practices.&nbsp;
As Dr. Scott noted, the financial stress can be severe enough to drive some physicians out of independent practice, pushing them to seek employment in larger health care systems or retire early.
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">What's Next?</h2>
Congress is expected to consider the Bipartisan Medicare Patient Access and Practice Stabilization Act and similar proposals before the end of the year. The AMA and the American College of Surgeons (ACS) hope this will lead to a longer-term solution that provides predictable and fair Medicare reimbursement rates. A bipartisan group of over 200 members of Congress supported a letter to the House of Representatives calling for a legislative solution to prevent future Medicare pay cuts.
What happens with the upcoming cut and whether Congress can pass a bill to avert it remains to be seen. However, each year of temporary fixes increases the pressure to develop a more sustainable solution for <a href="https://www.benzinga.com/general/biotech/24/09/40694793/despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs">Medicare reimbursements</a>. Many are watching to see if this year will bring new actions to prevent annual cuts and ensure that Medicare patients continue to get the care they need from their providers.&nbsp;
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>

Personal Finance

Doctors' 3% Medicare Pay Cut – Could It Lead to Fewer Providers Accepting Medicare Patients?

ASML

ASML Spokesperson Says Co Was Hit By An Outage On Friday; Claims IT Issue Is Resolved And All Systems Recovered

WIIM

CBUS

Cibus shares are trading higher after the company reported better-than-expected Q3 sales result.

Article via <a href="https://elplanteo.com/mercado-de-cannabis-en-puerto-rico-entrevista-prich/">El Planteo</a>
"Puerto Rico is a paradise for a cannabis entrepreneur," says Jaime Rengifo, CEO of <a href="https://elplanteo.com/prich/">Prich Biotech</a>, often regarded as the largest <a href="https://www.benzinga.com/money/best-latin-american-cannabis-companies">cannabis company in Latin America</a>. Since his arrival on the island, Rengifo has closely observed how this relatively small region has become a Latin American leader in <a href="https://elplanteo.com/cannabis-medicinal/">medicinal cannabis</a>, with a local market now surpassing $250 million annually. For Rengifo, however, success isn't just about numbers, it's about the model, education and accessibility that have fostered sustained growth and elevated product quality.
Watch the full episode of <a href="https://www.youtube.com/live/TzYjAsaQiFc?si=Tk6kE5Vi-nmyw980">&#8220;El Planteo Live&#8221;</a> on <a href="https://www.youtube.com/live/TzYjAsaQiFc?si=Tk6kE5Vi-nmyw980">YouTube</a>.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="El DIAMANTE EN BRUTO del CANNABIS LATINO: el SECRETO de PUERTO RICO" width="500" height="281" src="https://www.youtube.com/embed/TzYjAsaQiFc?start=1200&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Rengifo attributes Puerto Rico's progress in <a href="https://www.benzinga.com/cannabis">medicinal cannabis</a> to a functional regulatory system that allows patients to acquire medical marijuana from dispensaries located throughout the island. "People have access, patients can access products, in various formulations, various formats," he explains, referring to the range of consumption options available in Puerto Rico, which includes capsules, concentrates, <a href="https://elplanteo.com/comestibles-de-marihuana-guia-para-su-consumo/">edibles</a>, oils and even transdermal patches. While smoking cannabis is prohibited, the law allows for <a href="https://www.benzinga.com/topic/vaping">vaping</a>, an adjustment he believes has attracted a broader, more responsible consumer base.
See also: <a href="https://www.benzinga.com/markets/cannabis/23/09/33840003/latin-americas-best-kept-cannabis-secret-meet-the-biggest-marijuana-company-in-the-region">Latin America&#8217;s Best-Kept Cannabis Secret: Meet The Biggest Marijuana Company In The Region</a>
<h2 class="wp-block-heading">Education And Accessibility: Puerto Rico's Formula For Effective Medicinal Cannabis</h2>
For Rengifo, Puerto Rico's real triumph isn't just having an industry that works, but in how it works. He says the key lies in education and ensuring that access to medicinal cannabis is a right, not a privilege.
As CEO of Prich Biotech, Rengifo has championed educational programs to help both patients and doctors understand the benefits and correct use of the plant. "I don't see a reason why we should charge for a license [medical marijuana card] to obtain cannabis products," he says, adding that the system should ease access to treatments rather than complicate it with fees or unnecessary restrictions. "I believe cannabis is a therapeutic product."
Looking toward 2025, Rengifo and his team at Prich Biotech aim to further expand the reach of medicinal cannabis in Puerto Rico, particularly among senior citizens and military veterans &#8211; two groups he says could greatly benefit from the market. Just last week, Prich Biotech hosted an event targeting the baby boomer community. He said a surprising number of seniors not only showed interest in cannabis but were already familiar with its benefits.
"I really thought seniors would have a cultural barrier against cannabis," he admits. Yet the response was so positive that Prich Biotech is already planning a large-scale educational campaign for 2025 to reach more patients and reduce the stigma around medicinal cannabis use.
<h2 class="wp-block-heading">Challenges And Opportunities In A Responsibly Growing Cannabis Market </h2>
Rengifo recognizes that maintaining a competitive industry requires not only investment but ongoing adaptation. In Puerto Rico, he notes, cannabis initially had high prices, due partly to the early costly business models. However, as the market has matured, prices have dropped and the range of offerings has diversified. For him, this is crucial to popularize medicinal cannabis. "I can't keep prices high if I want to expand the industry and transform it," he explains.
Part of Rengifo&#8217;s strategy has been to optimize all cultivation and production processes at Prich Biotech. "We've automated production, standardized our cultivation processes," he says. Today, Prich Biotech can produce more grams of cannabis per square foot, maintaining consistent quality levels of <a href="https://elplanteo.com/que-es-el-thc/">THC</a> and <a href="https://elplanteo.com/que-es-el-cbd/">CBD</a>, making them, as he puts it, "very competitive in the market."
<h2 class="wp-block-heading">Puerto Rico's Potential: Preparing For A Cannabis Export Scenario</h2>
Rengifo envisions Puerto Rico not only as a regional model but as a potential benchmark for the global medicinal cannabis industry. The island, located about 1,000 miles southeast of Miami, Florida, boasts a historical pharmaceutical presence and robust infrastructure, which he believes could underpin the cannabis industry if U.S. laws move toward rescheduling or descheduling the plant at the federal level.
"We are preparing for the future," he says, noting that Prich Biotech is investing in Good Manufacturing Practices (GMP) certifications and standards that could allow it to export to markets like Europe and the United States.
"Puerto Rico is an island where all major pharmaceutical companies have a production facility… and cannabis, too, will become a valuable resource for Puerto Rico," Rengifo emphasizes. With a regulatory framework that models pharmaceutical quality standards, Puerto Rico, a US territory, could emerge as a leader in exporting medicinal cannabis—a goal Rengifo and his team are set on achieving.
Rengifo's vision, combined with Prich Biotech's focus on accessibility, education and efficiency paints a promising picture for Puerto Rico's medicinal cannabis industry. "This is a diamond in the rough," he says, and the journey is just beginning.
Cover image made with AI.

Latin America

Interview

'Diamond In The Rough' Of Latin American Cannabis: Puerto Rico's Success Secret Explained

Raymond James analyst Brian Vaccaro maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Strong Buy and raises the price target from $22 to $25.

FWRG

Raymond James Maintains Strong Buy on First Watch Restaurant Gr, Raises Price Target to $25

Citigroup analyst Fatima Boolani maintains Datadog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) with a Buy and raises the price target from $150 to $157.

DDOG

Citigroup Maintains Buy on Datadog, Raises Price Target to $157

NUTX

Nutex Health shares are trading higher after the company reported better-than-expected Q3 sales results.

TOST

Watching Toast; Shares See Volume To The Upside Amid Comments Live On CNBC From Josh Brown

Betting against Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and CEO Elon Musk might not be a successful strategy, as the world's richest man frequently proves triumphant with his <a href="https://www.benzinga.com/general/education/24/06/39547388/happy-birthday-elon-musk-53-facts-and-figures-about-tesla-spacex-ceo-on-his-53rd-birthday">various companies and ventures.</a>
Many people have bet against Musk and lost over the years, including billionaire Bill Gates. Here's a look back at Gates' infamous short bet against Tesla and how much investors could have made betting on Musk instead.
What Happened: Tesla stock is up 30% over the last week, helped by Donald Trump's win in the 2024 presidential election and the belief that the new president will be good for <a href="https://www.benzinga.com/markets/equities/24/11/41832876/elon-musk-shines-in-trump-sweepstakes-a-big-win-for-tesla-dan-ives-thinks-so">Musk and the company.</a>
With Musk endorsing Trump for the 2024 election and campaigning for him, the billionaire will now turn his attention to helping work on government efficiencies under the new president.
Musk's new role could lead more people to bet against him, with some put off by his political leanings and others speculating that his time commitment to Trump could impact Tesla.
Past history shows that betting against Musk hasn't yielded good results for many.
One person betting against Musk was revealed to be Microsoft co-founder Gates. In a February appearance on the "Joe Rogan Experience" podcast, Musk revealed that he believed Gates had a short position on Tesla stock.
"I also heard that at one point he had a large short position. I don't know if that's true or not, but it seems weird. People I know who know the situation pretty well, I asked them ‘are you sure?' and they said &#8216;yes,&nbsp;he has a huge short position on Tesla.&#8217;&nbsp;That didn't work out too well," Musk&nbsp;<a href="https://open.spotify.com/episode/2aB2swgyXqbFA06AxPlFmr" target="_blank" rel="noreferrer noopener">told&nbsp;</a>Joe Rogan.
Shortly after the comments from Musk, Gates was&nbsp;<a href="https://www.cnbc.com/video/2021/02/18/bill-gates-tesla-elon-musk-green-economy.html" target="_blank" rel="noreferrer noopener">interviewed&nbsp;</a>by CNBC's&nbsp;Andrew Ross Sorkin.
"What Elon's done with Tesla is fantastic," Gates said. "We need more Elon Musks."
Gates was asked directly if he was short Tesla stock.
"I don't talk about my investments," Gates replied, failing to deny the accusation.
In April 2022,&nbsp;<a href="https://www.benzinga.com/news/22/04/26775590/leaked-chats-show-musk-confronted-bill-gates-about-shorting-tesla-heres-what-they-discussed" target="_blank" rel="noreferrer noopener">leaked texts between Gates and Musk</a>&nbsp;revealed that Gates was still short the stock. Ahead of a proposed meeting between the two billionaires, Musk asked Gates via text if he still held a short position on Tesla.
"Sorry to say I haven't closed it out," Gates said. "I would like to discuss philanthropy possibilities."
Musk&#8217;s reply to Gates was straightforward and sharp.&nbsp;"Sorry, But I cannot take your philanthropy on climate change seriously when you have a massive, short position against Tesla, the company doing the most to solve climate change."
Musk told a user on Twitter that the texts were real.
Gates has praised Musk for what he has done for electric vehicles but has also said that more should be done for other clean energy initiatives.
"It's important to say that what Elon did with Tesla is one of the greatest contributions to climate change anyone's ever made. And you know, underestimating Elon is not a good idea," Gates&nbsp;<a href="https://www.nytimes.com/2021/02/15/opinion/sway-kara-swisher-bill-gates.html?showTranscript=1" target="_blank" rel="noreferrer noopener">told&nbsp;</a>the New York Times.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Investing $1,000 in Tesla Stock:&nbsp;The comments by Gates on CNBC and the leaked texts, which Musk confirmed to be real, highlight that Gates likely was short Tesla stock.
The big questions are: When did Gates go short on Tesla, and is he still short?
Short sellers of Tesla in 2022&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/12/30186916/tesla-short-sellers-have-15b-in-2022-profits-and-they-are-still-piling-on" target="_blank" rel="noreferrer noopener">enjoyed strong returns,</a>&nbsp;with shares down over 60% on the year. Musk once estimated that Gates would need $1.5 billion to $2 billion to close out his $500 million short bet on Tesla.
Using the appearance on the Joe Rogan Experience podcast as a starting point, investors could have seen an opportunity to bet with Musk and Tesla and go against Gates being short.
An investor could have purchased 3.74 shares of Tesla at the time with $1,000 based on a split-adjusted price of $267.09. The $1,000 investment would be worth $1,190.07 today, based on a price of $318.20 for Tesla at the time of writing.
While the 19.0% hypothetical return seems mild, it could have been much better for investors who properly timed their trades.
The $1,000 investment from February 2021 would have been worth $1,533.29 in November 2021, up 53.3%, when Tesla hit all-time highs.
Tesla stock traded between $24.08 and $235.22 in 2020, a year that could have seen Gates initiate his short position. The average share price for Tesla was a split-adjusted $96.67.
Investors who put $1,000 into Tesla in 2020 when Gates may have initiated his short position could have bought 10.34 shares based on the yearly average. The same $1,000 investment would be worth $3,290.19 today, up 229%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/11/41752565/if-you-invested-1-000-in-tesla-stock-the-first-time-elon-musk-was-on-the-joe-rogan-podcast-here">If You Invested $1,000 In Tesla Stock The First Time Elon Musk Was On The Joe Rogan Podcast, Here&#8217;s How Much You&#8217;d Have Now</a></li>
</ul>
This article was previously published by Benzinga and has been updated.
Image created with photos from Shutterstock.

Education

TSLA

If You Invested $1,000 In Tesla Stock When Bill Gates Shorted The Stock, Here's How Much You'd Have Today

APYX

Apyx Medical shares are trading higher after the company reported better-than-expected Q3 financial results. The stock initially traded lower, but it has since reversed.

Citigroup analyst Steven Zaccone maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Neutral and lowers the price target from $140 to $134.

Citigroup Maintains Neutral on Williams-Sonoma, Lowers Price Target to $134

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the first quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -$1.69. This was below the analyst estimate for EPS of -$1.44.</li><li>The company reported revenue of $1.39 million.</li><li>This was 4.21% worse than the analyst estimate for revenue of $1.45 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ptpi-stock-earnings-petros-pharmaceuticals-for-q1-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024

Analyst Naz Rahman from Maxim Group maintained a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and keeping the price target at $4.0...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Strategic Shift to OTC Market and Positive Regulatory Prospects

Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Petros Pharmaceuticals (PTPI – Research Report). The associated price target ...

Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!



Moving stocks this morning are clinical trail updates, an earnings report, acquisition news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Neo-Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/">NCI</a>) stock is rocketing more than 60% alongside heavy pre-market trading.</li>



<li>Sify Technologies Limited &ndash; Rights&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) shares are soaring over 29% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">before their delisting next week</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is surging more than 28% <a href="https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-120-today/">with clinical trial news</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) shares are gaining over 24% with strong early morning trading.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) stock is increasing more than 17% on heavy early morning trading.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are rising over 16% today.</li>



<li>Broadcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/">AVGO</a>) stock is heading 13% higher on <a href="https://www.barrons.com/articles/broadcom-stock-split-earnings-0c75392f">Q2 earnings and stock split plans</a>.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are climbing more than 11% without any clear news today.</li>



<li>CaliberCos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/">CWD</a>) stock is jumping over 11% this morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are up more than 10% </li>
</ol><h2>10 Top Losers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is crashing over 52% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318390446&amp;type=PDF&amp;symbol=IONM&amp;cdn=e3ce016dbdad608e6e12f639f088590d&amp;companyName=Assure+Holdings+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-06-12">terminating a merger agreement</a>.</li>



<li>DDC Enterprise (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ddc-stock-quote/">DDC</a>) shares are plummeting more than 28% after <a href="https://www.marketwatch.com/story/ddc-enterprise-shares-surge-after-purchase-of-omsom-2ae3de86?mod=markets">rallying yesterday on an acquisition</a>.</li>



<li>Cara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cara-stock-quote/">CARA</a>) stock is diving over 20% alongside <a href="https://www.nasdaq.com/press-release/cara-therapeutics-announces-outcome-part-kourage-1-study-evaluating-oral">clinical trial results</a>.</li>



<li>Petros Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) shares are tumbling more than 18% on Thursday morning.</li>



<li>PainReform (NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/">PRFX</a>) stock is taking an over 16% beating this morning.</li>



<li>J.Jill (NYSE:<a href="https://investorplace.com/stock-quotes/jill-stock-quote/">JILL</a>) shares are falling more than 16% after <a href="https://www.nasdaq.com/press-release/jjill-announces-pricing-public-offering-common-stock-2024-06-12">pricing a public offering</a>.</li>



<li>EpicQuest Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/eeiq-stock-quote/">EEIQ</a>) stock is dropping over 16% this morning.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) shares are decreasing more than 14% today.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is declining over 12% as it <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">comes off a recent rally</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Petros Pharmaceuticals (PTPI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahma...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic Advancements

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the second quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -37 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $1.42 million.</li><li>This was 1.50% better than the analyst estimate for revenue of $1.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ptpi-stock-earnings-petros-pharmaceuticals-for-q2-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) yesterday. The company's shares closed ye...

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and decreased the price target to $1...

Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals' OTC Stendra

The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). John Shulman and Greg Bradley, both members of the board of directors at Petros P...

Board Reshuffle at Petros Pharmaceuticals Following Resignations

An update from Petros Pharmaceuticals ( ($PTPI) ) is now available. Petros Pharmaceuticals has amended its employment agreement with President Fady...

Petros Pharmaceuticals Amends President's Employment Terms

AEMD

AVGO

CARA

EEIQ

IONM

JILL

LGVN

PRFX

PTPI

ROMA

SIFYR

SQNS

VSME

XPON

Biotech

Contracts

Press Releases

Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health

Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health

Health Care

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Events

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Comments

Petros Pharma

Petros Pharma (PTPI) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO